

HEMISPHERX BIOPHARMA INC  
Form 8-K  
July 20, 2011

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)  
July 15, 2011

HEMISPHERX BIOPHARMA, INC.  
(Exact name of registrant as specified in its charter)

|   |                                     |   |
|---|-------------------------------------|---|
| Delaware<br>(state or other jurisdiction of<br>incorporation) | 0-27072<br>(Commission File Number) | 52-0845822<br>(I.R.S.<br>Employer Identification No.) |
|---|-------------------------------------|---|

|   |                     |
|---|---------------------|
| 1617 JFK Boulevard, Philadelphia,<br>Pennsylvania<br>(Address of principal executive offices) | 19103<br>(Zip Code) |
|---|---------------------|

Registrant's telephone number, including area code: (215) 988-0080

---

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Section 5 – Corporate Governance and Management

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective July 15, 2011, the Company has terminated the full-time employment status of Russel J. Lander, Ph.D., Vice President of Process and Analytical Development.

2

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HEMISPHERX BIOPHARMA, INC.

July 20, 2011

By: /s/ William A. Carter  
William A. Carter M.D.,  
Chief Executive Officer

3

---